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Gene duplication is a major source of genetic
variation that has been shown to underpin the evo-
lution of a wide range of adaptive traits [1, 2]. For
example, duplication or amplification of genes en-
coding detoxification enzymes has been shown to
play an important role in the evolution of insecticide
resistance [3–5]. In this context, gene duplication
performs an adaptive function as a result of its
effects on gene dosage and not as a source of func-
tional novelty [3, 6–8]. Here, we show that dupli-
cation and neofunctionalization of a cytochrome
P450, CYP6ER1, led to the evolution of insecticide
resistance in the brown planthopper. Considerable
genetic variation was observed in the coding
sequence of CYP6ER1 in populations of brown
planthopper collected from across Asia, but just
two sequence variants are highly overexpressed in
resistant strains and metabolize imidacloprid. Both
variants are characterized by profound amino-acid
alterations in substrate recognition sites, and the
introduction of these mutations into a susceptible
P450 sequence is sufficient to confer resistance.
CYP6ER1 is duplicated in resistant strains with indi-
viduals carrying paralogs with and without the gain-
of-function mutations. Despite numerical parity in
the genome, the susceptible and mutant copies
exhibit marked asymmetry in their expression with
the resistant paralogs overexpressed. In the primary
resistance-conferring CYP6ER1 variant, this results
from an extended region of novel sequence up-
stream of the gene that provides enhanced expres-
sion. Our findings illustrate the versatility of gene
duplication in providing opportunities for functional
and regulatory innovation during the evolution of an
adaptive trait.268 Current Biology 28, 268–274, January 22, 2018 ª 2017 The Auth
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We previously demonstrated that resistance to the insecticide
imidacloprid in the brown planthopper (BPH), Nilaparvata
lugens, is associated with the overexpression of the cyto-
chrome P450, CYP6ER1 [9]. To explore if qualitative changes
in this P450 also play a role in resistance, we first sequenced
the complete coding cDNA of CYP6ER1 in field populations of
BPH collected from across Asia that all exhibit resistance
to imidacloprid (Tables S1 and S2). Comparison of the se-
quences obtained with a reference sequence (CYP6ER1vL)
derived from a lab-susceptible strain (NLS, Table S1) identified
a total of 114 polymorphic sites that result in 27 amino-
acid alterations (Figures 1A and S1A). These nucleotide se-
quences resolved to seven unique amino acid sequence vari-
ants: CYP6ER1vA, CYP6ER1vB, CYP6ER1vC, CYP6ER1vD1,
CYP6ER1vD2, CYP6ER1vE, and CYP6ER1vF (Figures 1A,
S1A, and S1B).
The relative expression of the different CYP6ER1 variants in
field populations of BPH was assessed by cDNA cloning and
sequencing and using variant-specific qPCR. This revealed
that just two of the CYP6ER1 variants are highly expressed in
strains from field populations:CYP6ER1vAwas themajor variant
expressed in strains from Thailand, Vietnam, and Indonesia,
whereas CYP6ER1vB was expressed in strains originating from
India (Figures 1B and 1C). The expression of one predominant
sequence variant in imidacloprid resistant populations of BPH
in these regions suggests that CYP6ER1vA and CYP6ER1vB
may play a primary role in resistance.
To test this, we expressed CYP6ER1vA, CYP6ER1vB, the
lab susceptible variant CYP6ER1vL, and its closest relatives
observed in the field, CYP6ER1vF and CYP6ER1vC, in vitro
and examined their capacity to metabolize imidacloprid. Liquid
chromatography tandem mass spectrometry (LC-MS/MS) anal-
ysis demonstrated that CYP6ER1vA and, to a lesser extent,
CYP6ER1vB are effective metabolizers of imidacloprid, convert-
ing it to 4/5-hydroxy imidacloprid and 6-chloronicotinic acid
(6-CNA) (Figure 1D). In contrast, no significant metabolism
of imidacloprid was observed in the case of CYP6ER1vC,
CYP6ER1vL, or CYP6ER1vF (Figure 1D).ors. Published by Elsevier Ltd.
commons.org/licenses/by/4.0/).
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Figure 1. Characterization of CYP6ER1 Variants in BPH Populations
(A) Number and type of nucleotide polymorphisms in different CYP6ER1 variants relative to CYP6ER1vL, the variant observed in the lab-susceptible strain.
(B and C) Relative expression of CYP6ER1 variants in imidacloprid-resistant BPH field strains (NLF1-8) and a susceptible strain (NLS), as determined by cDNA
cloning and sequencing (B), and variant-specific QPCR (C). In (C), letters above bars are used to denote significant (p = < 0.01 in all cases) differences
in expression between variants within each strain as assessed by one-way ANOVA with post-hoc Tukey HSD. Error bars in (C) indicate 95% confidence
intervals (n = 4).
(D) Metabolism of imidacloprid by recombinantly expressed CYP6ER1 variants. NADPH-dependent conversion of imidacloprid to 4/5-hydroxy imidacloprid
(IMI-OH) and 6-chloronicotinic acid (6-CNA) is shown. Error bars indicate 95% confidence intervals (n = 3).
See also Figure S1 and Tables S1 and S2.To explore which amino acid polymorphisms in CYP6ER1vA
and CYP6ER1vB are responsible for imidacloprid metabolism,
we first mapped polymorphisms in all CYP6ER1 variants to
important known P450 domains (Figures 2A and S1A). This
highlighted two features unique to these variants. First, both
CYP6ER1vA and CYP6ER1vB share an amino-acid substitution
in substrate recognition site (SRS) 4 at position 318, where a
threonine in all other variants is replaced with a serine. Signifi-
cantly, this occurs at a highly conserved position in a P450
signature sequence [A/G]GX[E/D]T[T/S] in helix I, known as
the oxygen-binding motif. The second alteration unique to
CYP6ER1vA/B is the deletion of an amino acid in SRS5 in
both variants. In CYP6ER1vA, this occurs at Ala375 and is
immediately followed by an alanine to glycine substitution,
whereas in CYP6ER1vB, a proline is deleted at position 377.
To predict the effect of these amino acid changes on imidaclo-
prid binding, CYP6ER1 was computationally modeled and
docking simulations of imidacloprid within the active site of
CYP6ER1vL, CYP6ER1vA, and CYP6ER1vB performed (Fig-
ures 2B, 2C, and 2D). This revealed that T318 and A376, along
with additional residues, create the hydrophobic interface of
the binding cavity (Figure 2B). In CYP6ER1vA, T318S in combi-nation with A376G increases the conformational space acces-
sible to imidacloprid between these two positions (Figure 2C).
Although less pronounced, this is also true for CYP6ER1vB,
where the T318S mutation comes together with an alanine at
position 376 (Figure 2D). In this instance, due to the proline
deletion, the fold of CYP6ER1vB is shifted slightly away from
the I-helix substitution with the consequence of a similar
gap opening. These alterations are consistent with the hydrox-
ylation capacity seen for individual CYP6ER1 variants when
functionally expressed and are strong candidates for the
gain-of-function observed.
To validate the predictions made by homology modeling,
we employed site-directed mutagenesis in combination with
functional expression in vivo. For this, a series of amino-acid
alterations were introduced into the susceptible CYP6ER1vL
sequence as follows: T318S, P377del, A375del+A376G,
T318S+P377del, and T318S+A375del+A376G. A series of trans-
genic Drosophila lines were created that ubiquitously express
each of these mutated P450s, or the wild-type variant
CYP6ER1vL, and their sensitivity to imidacloprid was assessed
(Table 1). The T318S substitution, shared by both variants, re-
sulted in amarked (20-fold) and significant increase in resistanceCurrent Biology 28, 268–274, January 22, 2018 269
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Figure 2. Modeling the Active Site of CYP6ER1 Reveals the Impact of Amino Acid Alterations on Imidacloprid Binding
(A) Amino-acid alignment of CYP6ER1 variants highlighting substitutions and deletions within substrate recognition sites four and five (boxed in red).
(B–D) Protein homology modeling for 3 different CYP6ER1 variants (upper row), showing key residues surrounding the catalytic site. Amino-acid positions
T318/A376 in CYP6ER1vL (B), S318/G376 in CYP6ER1vA (C), and S318/A376 in CYP6ER1vB (D) are in close proximity (spacefill representation). Imidacloprid
docking into the active site is illustrated (lower row) by colored volumes, constituting an envelope around an ensemble of possible binding poses.
See also Figure S1.compared to the wild-type susceptible variant. Deletion of
Pro377, as seen in CYP6ER1vB, provided a more moderate,
but significant, 4.5-fold increase in resistance. In contrast, the
A375del+A376G alteration observed in CYP6ER1vA conferred
higher levels (20-fold) of resistance to imidacloprid. When
T318S was combined with P377del (as seen in CYP6ER1vB),
an epistatic interaction was observed, with the resistance
conferred by the double mutation (20-fold) less than the sums
of the effects of the component single mutations. In contrast,
an additive interaction was observed when T318S was com-
bined with A375del+A376P (as observed in CYP6ER1vA), with
this combination exhibiting the highest resistance of all mutant
lines (35-fold). These data are consistent with the relative
efficiency of imidacloprid hydroxylation by CYP6ER1vA and
CYP6ER1vB observed in vitro (Figure 2D) and convincingly
demonstrate the adaptive nature of the genetic alterations
observed in these isozymes.
To examine if the high levels of genetic variation inCYP6ER1 in
BPH field populations results, in part, from gene copy number
variation (CNV), we resequenced the genomes of three BPH270 Current Biology 28, 268–274, January 22, 2018strains that primarily express CYP6ER1vA (NLF2), CYP6ER1vB
(NLF7), or CYP6ER1vL (NLS), respectively. Reads were mapped
to the coding sequence of CYP6ER1 and two single-copy refer-
ence genes in the genome of BPH: the P450 CYP6AY1 and
the voltage-gated sodium channel (VGSC); and read coverage
across each gene was compared between strains (Figures
3A–3F). No significant shift in coverage was observed be-
tween the three strains across CYP6AY1 or VGSC. However,
an approximately 2-fold increase in read depth was observed
over the coding sequence of CYP6ER1 between the two resis-
tant strains NLF2 and NLF7 and the susceptible strain NLS, sug-
gesting that CYP6ER1 is duplicated in the field strains. qPCR
confirmed this finding, with the copy number of CYP6ER1
2.2-fold higher in NLF7 and 1.9-fold higher in NLF2 than in
NLS. The mean cycle threshold values in qPCR of CYP6ER1
and the single-copy reference gene in NLS were essentially the
same (23.50 [SEM = 0.04] and 23.62 [SEM = 0.08], respectively),
indicating that CYP6ER1 is present as a single copy in the
haploid genome of NLS and two copies in NLF2 and NLF7 (Fig-
ures 3G and 3H).
Table 1. Log-Dose Probit-Mortality Data for Imidacloprid against Female Transgenic Drosophila-Expressing CYP6ER1 Mutants
Strain LC50 [mg/L-1] 95% CL Slope (+/ SD) Resistance Ratio to vL
No transgene 111.1 45-233 1.373 ± 0.287 -
Wildtype (vL) 53.1 31.4-82.6 1.864 ± 0.328 -
T318S 1062 531-2292 1.103 ± 0.183 20.0
P377del 237 101.4-520 1.324 ± 0.262 4.5
A375del+A376G 1062 752-1501 2.082 ± 0.264 20.0
T318S+P377del 1063 442-2680 1.54 ± 0.356 20.0
T318S+A375del+A376G 1857 905-4229 1.448 ± 0.293 35.0
The wildtype reference line expresses CYP6ER1vL. No transgene: Flies of the same genetic background but minus the transgene.To explore if one or both of the gene copies in resistant BPH
individuals carry the resistance-conferring mutations, 30 indi-
viduals of the NLF2 and NLF7 strains were genotyped by PCR
and direct sequencing. All individuals of the two strains scored
as heterozygous for the diagnostic resistance mutations that
characterize CYP6ER1vA and CYP6ER1vB, respectively (Fig-
ures S2A and S2B). This observed excess of apparent heterozy-
gosity is a characteristic signature of a duplicated gene and
demonstrates that individuals of both strains carry CYP6ER1
copies with and without the resistance conferring mutations.
To more precisely confirm which variants are present in these
two strains, we cloned and sequenced amplified products from
three individuals of each strain. For individuals of NLF2we recov-
ered two different sequences in equal abundance; the first car-
ried the indels/SNPs that define CYP6ER1vA, while the second
carried SNPs diagnostic for CYP6ER1vC (Figures 3I, S2C, and
S2D). Sequencing of colonies from NLF7 individuals again
recovered two alternative sequences in equal abundance: the
first corresponded to CYP6ER1vB, while the SNP profile of the
second most closely matched CYP6ER1vF (Figures 3I, S2C,
and S2D). Thus, taken together with functional analyses (Fig-
ure 1D), these data reveal that the genomes of individuals of
both resistant strains have CYP6ER1 copies that encode the ca-
pacity to metabolise imidacloprid and those that do not.
To examine the expression of the different gene copies
observed in NLF2 and NLF7, we repeated these experiments
but used RNA extracted from individuals of each strain as
template in RT-PCR. Again, we only observed sequences
representing CYP6ER1vA and CYP6ER1vC in individuals of
NLF2; however, CYP6ER1vA represented > 90% of the clones
sequenced (Figures 3I and S2D). Similarly, in the case of NLF7,
we only observed sequences representing CYP6ER1vB and
CYP6ER1vF, with the former representing > 90% of the se-
quences recovered (Figures 3I and S2D). Thus, the duplicate
genes exhibit marked divergence in their expression, with the
copy with the gain-of-function mutations overexpressed.
To explore the molecular basis of this and simultaneously
examine the genomic architecture of different CYP6ER1 vari-
ants, we employed a gene capture approach. This allowed the
close-to-complete gene sequence of CYP6ER1vL,CYP6ER1vA,
CYP6ER1vB, CYP6ER1vC, and CYP6ER1vF to be assembled
(Figure 3J). Considerable variation was seen in intron size
and sequence between different CYP6ER1 variants (Figures 3J
and S3). This was particularly pronounced in the case of
CYP6ER1vA and CYP6ER1vB. For example, in CYP6ER1vA,
intron 1 is > 4.9 kb in size in contrast to 4 kb in other variants,and intron 4 is just 316 bp in size compared to an average size
of 5 kb in other variants. In the case of CYP6ER1vB, intron 2
was much larger than in all other variants (5,478 bp compared
to an average of 3,302 bp), with this expanded intron size result-
ing from an internal duplication that included the last 123 bp of
exon 3. This pseudo-exon was never observed in CYP6ER1vB
transcripts, likely due to the loss of the splice site consensus
sequence upstream of the duplicated region.
Five putative promoter variants were identified by gene cap-
ture, four of which could be linked to CYP6ER1vA, CYP6ER1vB,
CYP6ER1vC, and CYP6ER1vL (Figures 3K and S4). Surprisingly,
only the promoter associated with CYP6ER1vA matched the
sequence upstream of CYP6ER1 on scaffold KN153994.1 of
the reference genome [10]. The remaining four promoter variants
do not show sequence similarity with any other scaffold in the
genome. Indeed, alignment of the promoter variants reveals a
clear break point 104 bp upstream of the start codon in
CYP6ER1vA, with the sequence of this variant completely
diverging from the other four variants after crossing this point
(Figures 3K and S4). We used reporter gene assays to explore
the effect of this on gene expression. No significant differences
were seen in reporter gene expression driven by a1.8 kb region
of the promoters of CYP6ER1vB, CYP6ER1vC, and CYP6ER1vL
(Figure 3L). This finding suggests that the overexpression of
CYP6ER1vB seen in resistant BPH strains results from either
trans-acting factors or cis-acting elements outside of the region
analyzed. In contrast, we observed a significant (up to 9.5-fold)
increase in expression driven by the promoter of CYP6ER1vA in
comparison to all other promoter variants (Figure 3L). This
suggests that cis-acting elements in the region upstream of
CYP6ER1vA, derived from the novel genomic sequence, are
responsible for the high expression of this variant in BPH popula-
tions across Southeast Asia.
DISCUSSION
Our data show that two CYP6ER1 sequence variants are highly
expressed in imidacloprid resistant field populations of BPH
from across Asia. Both variants are defined by the same or
similar mutations that confer the capacity to metabolise imida-
cloprid but, despite this, appear to have independent origins—
CYP6ER1vA evolving in southeast Asia and CYP6ER1vB in
India. Cases of parallel evolution can shed light on the repeat-
ability of evolution while also providing insight into molecular
constraints. In the case of CYP6ER1, the repeated acquisition
of amino-acid alterations at the same or similar sites suggestsCurrent Biology 28, 268–274, January 22, 2018 271
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that only modification of these sites bring about the func-
tional change in imidacloprid sensitivity while satisfying other
constraints.
We demonstrate that CYP6ER1 is duplicated in resistant
strains and show that resistant individuals carry one copy
with the gain-of-function mutations and one without. In most
examples of gene duplication or amplification of detoxification,
enzymes associated with metabolic resistance duplicates are
identical and are retained because of the clear benefits of
increased gene dosage [3, 4, 7, 8]. In contrast, in this example,
copying of the ancestral CYP6ER1 gene would not immediately
provide a fitness benefit in the presence of insecticide, as it lacks
the capacity to metabolise imidacloprid. Rather, the evolution of
the novel, selectively beneficial function of the mutant copy of
CYP6ER1, which was not present in the ancestral gene, is a
compelling example of neofunctionalization [1]. In the classical
model outlined by Ohno, gene duplication creates redundancy,
allowing the second gene copy, under relaxed constraint, to
accrue mutations, which, if adaptive, are fixed under selection
[11]. Several of our findings are consistent with this model and
suggest that gene duplication was required to free CYP6ER1
from functional constraint and permit the acquisition of muta-
tions that led to resistance. First, resistant BPH individuals retain
a wild-type copy of CYP6ER1 despite the fact that it encodes an
enzyme with no capacity to metabolise imidacloprid, suggesting
that it is important for organismal fitness. Second, the genetic al-
terations seen inCYP6ER1vA andCYP6ER1vB are profound, re-
sulting in the substitution of a highly conserved residue in SRS4
and the deletion of amino acids in SRS5. Although the native
substrate(s) of CYP6ER1 is unknown, it is reasonable to predict
that the nature and location of these alterations would alter the
binding and subsequent enzymatic conversion of the natural
substrates of this enzyme. Finally, comparison of CYP6ER1
from BPH and its orthologs in white-backed planthopper
(Sogatella furcifera) and small brown planthopper (Laodelphax
striatellus) reveal that, while the two orthologous P450s diverge
from CYP6ER1 at > 30% of amino acids, they are completely
conserved at the site of the resistance mutations, where they
all have the wild-type residues, suggesting that these sites are
highly constrained.
Gene capture analyses revealed marked changes in
the genomic architecture of CYP6ER1vA and CYP6ER1vB
compared to other variants, including the putative single-copyFigure 3. Genomic Analyses of the CYP6ER1 Locus
(A–F) Coverage plots of DNA-seq reads from the NLS (imidacloprid susceptible) s
sequence of two reference single-copy genes: the voltage-gated sodium channe
(G and H) Copy number of CYP6ER1 in the NLF7 (G) and NLF2 (H) strains
intervals (n = 4). ***p < 0.001; one-way ANOVA with post hoc Tukey HSD.
(I) Number of sequenced colonies obtained of eachCYP6ER1 variant after cloning
individuals of the NLF2 and NLF7 strains. Error bars indicate 95% confidence lim
(J) Assembly of gene capture long reads reveals marked variation in intron size b
with the partially duplicated exon in CYP6ER1vB highlighted in red. Gaps illustra
(K) Alignment of different putative promoter variants of CYP6ER1 upstream of th
and black regions indicate sequence differences. Indels are indicated by gaps in th
all sequences for every position. Green indicates that the residue at the position i
red refers to very low identity for the given position. The position of the breakpoi
(L) Reporter gene activity (normalized to renilla fluorescence) of CYP6ER1 prom
one-way ANOVA with post-hoc Tukey HSD. Error bars indicate 95% confidence
See also Figures S2, S3, and S4.ancestor CYP6ER1vL, strongly suggesting that the duplication
of CYP6ER1 predates the introduction of imidacloprid in the
early 1990s. Thus, gene duplication itself was not a de novomu-
tation occurring in response to insecticide use. Rather, our data
aremost parsimoniouswith amodel of evolutionary opportunism
with the exaptation of existing standing genetic variation (in this
case, CNV), when the environmental conditions changed, facili-
tating subsequent functional innovation.
A central question in evolutionary biology is the relative contri-
bution of functional versus regulatory divergence during the evo-
lution of new genes. In this regard, a significant finding of our
study was that, although resistant BPH individuals carry copies
of CYP6ER1 with and without resistance mutations, only the
mutant copy is highly expressed. We provide a molecular expla-
nation for this in the case of CYP6ER1vA with gene capture
revealing an extended region of novel sequence upstream of
this variant in comparison to all other variants. The extent and
size of this region of divergent sequence is consistent with a
duplication breakpoint, although we cannot exclude a large indel
upstream of this variant as an alternative possibility. Reporter
genes assays demonstrated that the novel sequence provides
cis-acting elements that result in the increased expression
of CYP6ER1vA. In the presence of insecticide, this increased
expression would be highly beneficial, likely explaining, in part,
why CYP6ER1vA is now the predominant variant expressed in
resistant BPH populations in Asia.
In summary, we provide a novel example of the evolution
of metabolic resistance by gene duplication and neofunctionali-
zation. In this case study, the chromosomal rearrangements
involved provided opportunities for functional and regulatory
innovation, once again highlighting the remarkable capacity of
gene duplication to drive the evolution of adaptive traits.STAR+METHODS
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Nilaparvata lugens: NLF3 strain Hau Giang, Vietnam This paper
Nilaparvata lugens: NLF4 strain Anjatan District, Indramayu,
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Nilaparvata lugens: NLF6 strain Koppal District, Karnataka State,
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Nilaparvata lugens: NLF8 strain Sidhikerra, Karnataka State, India This paper
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Insect strains
A laboratory-maintained strain ofN. lugens exhibiting susceptibility to imidacloprid (NLS) and eight field strains of BPH collected from
Thailand (NLF1), Vietnam (NLF2, NLF3), Indonesia (NLF4) and India (NLF5, NLF6, NLF7, NLF8) were reared in the laboratory on whole
rice plants (Oryza sativa L. ssp.) under controlled environmental conditions (26C/16h photoperiod). Year of collection is detailed in
Table S1. We have previously shown that all eight of the field strains exhibit resistance to imidacloprid (Table S2) [12].
The Drosophila melanogaster stock 13-20 [‘‘y1w67c23; P attP40 25C6,’’ ‘‘1;2’’] obtained from the University of Cambridge was
used to create all transgenic lines. Virgin females of this line were crossed to males of the Act5C-GAL4 strain [‘‘y[1] w[*]; P(Act5C-
GAL4-w)E1/CyO,’’’’1;2’’] (Bloomington Stock Center) to activate transgene expression (see below for description of methods). All
flies were reared on NutriFly food (NLS) at 24C. Only female flies 2-5 days post eclosion were used for insecticide bioassays.e2 Current Biology 28, 268–274.e1–e5, January 22, 2018
Insect cell lines
The Sf9 and High Five insect cell lines (ovarian cells from Spodoptera frugiperda and Trichoplusia ni respectively) were maintained in
suspension culture under serum-free conditions at 27C containing 25 mg/mL-1 gentamycin in SF-900 II SFM (GIBCO) and Express
Five SFM (GIBCO), respectively.
METHOD DETAILS
Identification and expression analysis of CYP6ER1 sequence variants
Total RNA was extracted from 4 pools of 8 adult hoppers of each strain using the ISOLATE II RNA Mini Kit (Bioline) and reverse tran-
scribed to cDNA using Superscript III reverse transcriptase (Invitrogen) followingmanufacturer protocols in both cases. Phusion DNA
polymerase (Thermo) was used to amplify the full coding sequence of CYP6ER1 following the manufacturers protocol and using
10 ng of cDNA as template in 50 ml reactions and the primers listed in Table S4. Thermocycling conditions consisted of an initial dena-
turation step at 98C for 30 s, followed by 35 cycles of 98C for 10 s, 55C for 20 s, 72C for 1 min, and a final extension at 72C for
5 min. Products were either direct Sanger sequenced using the primers detailed in Table S4 or cloned using the Strataclone Blunt
PCR Cloning kit (Stratagene) and sequenced using T3/T7 primers. Variant calling was carried out in Geneious version 9 (Biomatters),
and phylogeny performed in MEGA version six [13]. Expression of CYP6ER1 variants was initially assessed by PCR amplification of
the CYP6ER1 coding sequence followed by cloning and sequencing of 16 colonies per strain (as detailed above). Quantitative PCR
analysis of the expression of different CYP6ER1 variants was performed using the primers detailed in Table S4. PCR reactions (20 ml)
contained 10 ng of cDNA, 10 ml of SYBRGreen JumpStart Taq Readymix (Sigma), and 0.25 mmof each primer. Samples were run on a
Rotor-Gene 6000 (Corbett Research) using temperature cycling conditions of: 2 min at 95C followed by 40 cycles of 95C for 15 s,
57C for 15 s and 72C for 20 s. A final melt-curve step was included post-PCR (ramping from 72C–95C by 1C every 5 s) to check
for nonspecific amplification. The efficiency of PCR for each primer pair was assessed using a serial dilution of 100 ng to 0.01 ng of
cDNA. Each quantitative RT-PCR experiment consisted of three independent biological replicates with two technical replicates for
each. Data were analyzed in Microsoft Excel according to the DCT method [14], using the geometric mean of two reference genes
(actin and a2-tubulin) for normalization.
Heterologous expression of P450s
Natural and mutated CYP6ER1 variants andM. domestica NADPH-dependent cytochrome P450 reductase (CPR) (GenBank acces-
sion number Q07994) were codon optimized for expression in lepidopteran cells and obtained by gene synthesis (Geneart, CA, USA)
in the pDEST8 expression vector (Invitrogen). The PFastbac1 vector with no insert DNA was used to produce a control virus. The
recombinant baculovirus DNA was constructed and transfected into Sf9 cells using the Bac-to-Bac baculovirus expression system
(Invitrogen) according to themanufacturer’s instructions. The titer of the recombinant virus was determined following the protocols of
the supplier. High Five cells grown to a density of 2 3 106 cells/mL-1 were co-infected with recombinant baculoviruses containing
P450 and CPR at various MOI (multiplicity of infection) ratios to identify the best conditions. Control cells were co-infected with
the baculovirus containing vector with no insert (ctrl-virus) and the recombinant baculovirus expressing CPR using the same MOI
ratios. Ferric citrate and d-aminolevulinic acid hydrochloride were added to a final concentration of 0.1 mM at the time of infection
and 24 h after infection to compensate the low levels of endogenous heme in the insect cells. After 60 h, cells were harvested by
centrifugation, washed with PBS, and microsomes of the membrane fraction prepared according to standard procedures [15].
Briefly, pellets were homogenized for 30 s in 0.1M Na/K-phosphate buffer, pH 7.4 containing 1mM EDTA and DTT and 200mM
sucrose using a Fastprep (MP Biomedicals), filtered through miracloth and centrifuged for 10 min at 680 g at 4C. The supernantant
was then centrifuged for 1 h at 100,000 g at 4C, with the pellet subsequently resuspended in 0.1M Na/K-phosphate buffer, pH 7.6
containing 1mMEDTA andDTT and 10%glycerol using a Dounce tissue grinder. P450 expression and functionality was estimated by
measuring CO-difference spectra in reduced samples using a dual beamCary 300 UV-Vis Spectrophotometer (Agilent) and scanning
from 500 nm to 400 nm [15]. The protein content of samples was determined using Bradford reagent (Sigma) and bovine serum
albumin as a reference following the manufacturer’s instructions.
Metabolism assays and LC-MS/MS analysis
Metabolism of imidacloprid was assayed by incubating recombinant P450/CPR (2 pmol P450 / assay) or ctrl-virus/CPR microsomes
in 0.1 M potassium phosphate buffer pH 7.6 with an NADPH-regenerating system (Promega; 1.3 mM NADP+, 3.3 mM glucose-6-
phosphate, 3.3mMMgCl2, 0.4 U/mL
-1 glucose-6-phosphate dehydrogenase) and substrate (12.5 mM) at 27C for 1 h. The total assay
volume was 200 mL using three replicates for each data point. Microsomes incubated without NADPH served as a control. The assay
was quenched by the addition of ice-cold acetonitrile (to 80% final concentration), centrifuged for 10 min at 3000 g and the super-
natant subsequently analyzed by liquid chromatography-tandem mass spectrometry. Chromatography was performed using a
Waters UPLC utilizing a Waters Acquity HSS T3 (2.1x50 mm, 1.8mm) column. Solvents were water/0.1% formic acid and
acetonitrile/0.1% formic acid used in a 4 min gradient. The mass spectrometer used was a Sciex API4000 in positive ionization
mode for imidacloprid and its hydroxylated metabolite (MRM transitions: 256 > 175, 272 > 191, respectively). 6-CNA was measured
in negative ion mode using the ion transition 165 > 121. Quantification was performed by external calibration using reference
compounds. Recovery rates of parent compounds using microsomal fractions without NADPH were close to 100%.Current Biology 28, 268–274.e1–e5, January 22, 2018 e3
Homology modeling of CYP6ER1 and molecular docking simulation
3D models for CYP6ER1vA, CYP6ER1vB and CYP6ER1vL were generated by the advanced homology modeling tool within the
Schrodinger software suite [16]. Following a BLAST search for the most suitable template-fold all three protein models were con-
structed based on the crystal structure of human CYP3A4 (PDB-ID: 1TQN) and refined by an energy minimization step to remove
conformational strains and contacts. For the docking studies a catalytic oxygen atom was manually added to the heme iron center.
Imidacloprid was docked into the three CYP6ER1 variants using the virtual screening software package LeadIT 2.2.0 utilizing the
FlexPharm option [17]. The pharmacophore constraint [18] required a non-hydrogen-atomwithin a distance of 2.5 A˚ from the catalytic
oxygen. All resulting docking poses underwent hierarchical clustering using a script based on pairwise in-place RMSD values; for this
only non-hydrogen atoms were taken into account. The cut height for the cluster generation was 2.0. For each resulting cluster the
pose with the lowest FlexX docking rank was selected. This subset of cluster representatives was further reduced by removing all
poses where not at least one of the five membered ring atoms was within a distance of 2.5 A˚ (or less) from the catalytic oxygen.
For the models of vL, vA and vB the resulting pose spaces were then visually inspected and compared.
Transgenic expression of candidate genes in D. melanogaster
Wild-type (CYP6ER1vL) and mutant CYP6ER1 variants were synthesized and provided in the pUASTattB40 plasmid (Geneart, CA,
USA). Using the PhiC31 system, clones were transformed into the germline of a D. melanogaster strain carrying the attP40 docking
site on chromosome 2 [‘‘y1w67c23; P attP40 25C6,’’ ‘‘1;2’’]. The transgenic lines obtained were balanced and the integration of genes
confirmed by PCR and sequencing using Phusion DNA polymerase (Thermo) as detailed above with the primers detailed in Table S4.
Virgin females of the Act5C-GAL4 strain were crossed with UAS-gene-of-interest males. Bioassays were used to assess the suscep-
tibility of adult female flies to imidacloprid. Several concentrations were overlaid onto 1.5% agar containing 1% sucrose in standard
Drosophila vials and allowed to dry overnight at room temperature. 10-15 adult flies (two to five days post eclosion) were then added
to each vial and mortality assessed after 48 hr. Four replicates were carried out for each concentration. Control mortality was
assessed using vials containing agar/sucrose minus insecticide. Lethal concentrations (LC50 values) and 95% fiducial limits were
calculated by probit analysis using Genstat version 16 (VSN International).
Copy number analysis and sequencing of individual hoppers
Genomic DNA was extracted from multiple pools of 10 hoppers using the Plant DNeasy Mini kit (QIAGEN) and used to construct
PCR-free libraries. Libraries of each strain were sequenced across a single lane of an Illumina HiSeq2500 using a 250 bp paired-end
read metric. FastQC was used to check the quality of the raw reads obtained [19] and reads trimmed using Trim Galore [20]. In initial
attempts to estimate gene copy number the reads of each strain were mapped to the reference genome (sequenced from an inbred
line derived from a strain collected in Hangzhou, China, in 2008 [10], GenBank assembly accession number: GCA_000757685.1) us-
ing BWA-MEM [21] and CNV estimated using CNVseq [22] with data of each field strain compared to the lab susceptible strain. This
analysis failed to identify significant differences in copy number between the strains at the CYP6ER1 locus, likely because the single
scaffold of the reference genome where CYP6ER1 is located (KN153994.1) fails to accurately represent the genetic diversity
observed at this locus in different variants and strains resulting in, at best, only partial mapping of CYP6ER1-related reads. Thus,
in a second approach reads were mapped to the coding sequence of CYP6ER1 and two reference genes: the P450 CYP6AY1
and the voltage-gated sodium channel (VGSC), both of which are single copy genes in BPH, using BWA-MEM [21]. Read coverage
was then compared in 100bp non-overlapping windows across the coding sequence of the three genes using SAMtools [23]. Results
were validated with qPCR using DNA as template and two sets of primers (designed in conserved regions (variant non-specific) of the
gene) for CYP6ER1 listed in Table S4 and the conditions described above. Data were analyzed according to the DDCT method [24]
using the VGSC as a reference gene for normalization with the expression values of the four biological replicates obtained for each of
the two CYP6ER1 primer sets averaged.
For variant analysis on individual hoppers, DNA and RNA was extracted (as above) from individuals of the NLF2 and NLF7 strains
and used as template in PCR using Phusion DNA polymerase (Thermo) (as detailed above) and the primers detailed in Table S4which
amplify a region containing key SNPs that are diagnostic for different CYP6ER1 variants.
Gene capture
Approximately 2.5 ug of gDNA was extracted per strain from several pools of insects as detailed above and sent to Earlham Institute
for processing according to Roche’s NimbleGen gene capture protocol. The gDNA was sheared with a Covaris tube and size
selected within the range of 5-9 kb on a BluePippin. The pre-capture library was amplified for 6 rounds to increase the starting
material for the capture set up. The library was incubated with the baits (fifteen 100 nt baits per transcript) designed to cover the entire
1.5 kb coding sequence of all knownCYP6ER1 variants described in this study) at 47C for 22 hr. The post capture library was gener-
ated through 19 cycles of amplification of the bait extracted fragments. Each library was sequenced on a single SMRT cell (P6C4). To
minimize sequencing errors inherent in PacBio data only circular consensus (CCS) reads, generated from repeated passes of
polymerase over a single molecule, or raw reads that were error corrected using the Illumina reads for NLS, NLF2 and NLF7 were
used to assemble gene sequences. Assembly and bioinformatics analyses was conducted in Geneious version 9 (Biomatters). Error
correction of long Pacbio reads with short-read Illumina data was performed using proovread [25].e4 Current Biology 28, 268–274.e1–e5, January 22, 2018
Reporter gene assays
Promoter sequences were synthesized, subcloned into pGL3-Basic (Promega) and transformed into Library Efficiency DH5a
Competent Cells (Invitrogen). Plasmids were extracted with the GeneJet plasmid miniprep kit (Fermentas), sequenced and then
adjusted to 400 ng/ml for use in dual luciferase assays using the Sf9 insect cell line. Approximately 13 106 cells per well were plated
into 6-well plates 2 hr prior to transfection and allowed to reach 60%–70% confluency. Insect GeneJuice Transfection Reagent
(Novagen) was used for transfection of constructs and the Dual-Luciferase Reporter Assay (Promega) used for promoter activity
measurements according to the manufacturer’s protocols. 2 mg of reporter constructs and pGL3 without insert (as a control) was
co-transfected with 4 ng Renilla luciferase pRL-CMV using GeneJuice and incubated at 27C. 4 hr post-transfection, the transfection
mixture was removed and replacedwith supplementedGrace’s InsectMedium (GIBCO). Following further incubation at 27C for 48 h
and washing of cells with PBS, cells from each well were harvested in 500 mL passive lysis buffer (Promega) and luciferase activity
measured on aGloMax 20/20 (Promega). Construct luciferase activity was normalized to Renilla luciferase activity as instructed in the
manufacturer’s protocol.
QUANTIFICATION AND STATISTICAL ANALYSIS
All statistical analyses were performed in GraphPad Prism 7 (GraphPad Software). Significant differences in expression or copy
number in all QPCR experiments were determined using one-way ANOVA with post hoc Tukey HSD. Significant differences in the
number of colonies obtained for each variant for each strain in the cloning and sequencing of individuals was determined using a
paired t test. Significant differences in normalized reporter gene expression between promoter variants was determined using
one-way ANOVA with post hoc Tukey HSD. Statistical details of experiments (value of n, precision measures and definitions of
significance) are provided in figure legends.
DATA AND SOFTWARE AVAILABILITY
The sequences reported in this paper have been deposited in the GenBank database (accession numbers GenBank: MF970458,
GenBank: MF970459, GenBank: MF970460, GenBank: MF970461, GenBank: MF970462, and GenBank: MF970463).Current Biology 28, 268–274.e1–e5, January 22, 2018 e5
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Figure S1. Sequence characterisation of CYP6ER1 variants. Related to Figure 1. 
A) Amino acid alignment of CYP6ER1 variants. Key conserved P450 motifs and substrate 
recognition sites are annotated. B) Phylogenetic relationship of CYP6ER1 variants. Tree was 
generated using the Maximum Likelihood method and is drawn to scale, with branch lengths 
measured in the number of substitutions per site. Bootstrap replications were performed and the 
percentage of 1000 replications supporting each branch are shown. 
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Figure S2. CYP6ER1 genotyping of individuals of the NLF2 and NLF7 BPH strains using 
DNA and RNA as template in (RT-)PCR. Related to Figure 3. (A) Representative sequence 
traces obtained from direct sequencing of a diagnostic fragment of CYP6ER1 encompassing the 
resistance mutation sites in exon 6. DNA extracted from individuals of the NLF2 and NLF7 
strains was used as template in PCR. Two representative sequences of each strain are aligned 
to a representative sequence obtained from NLS (which has just one copy of CYP6ER1). Boxed 
regions indicate the sites of the A375del+A376G mutations in CYP6ER1vA and P377del in 
CYP6ER1vB (see also part C of this figure) and highlight the heterozygosity observed at these 
regions (overlapping chromatogram peaks). (B) Results of genotyping 27-30 individuals of the 
NLF2 and NLF7 for the resistance mutations that define CYP6ER1vA and CYP6ER1vB. (C) 
Alignment of a diagnostic CYP6ER1 sequence fragment from BPH individuals of resistant 
strains. Alignment shows representative sequence reads obtained from cloning and sequencing 
an amplicon containing SNPs and INDELs diagnostic for each of the unique CYP6ER1 variants 
using DNA extracted from individuals of the NLF2 and NLF7 strains. For reference the 
sequence of the eight CYP6ER1 variants is included. (D) Number of sequenced colonies 
obtained of each CYP6ER1 variant after cloning and sequencing PCR products amplified from 
either genomic DNA or mRNA of individuals of the NLF2 and NLF7 strains. 

Figure S3. Sequence analysis of the introns of different CYP6ER1 variants. Related to 
Figure 3. 
 Alignment of each intron is shown with a matrix of calculated sequence identity shown below. 
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Figure S4. Alignment of CYP6ER1 promoter variants. Related to Figure 3. A) Alignment of 
1750bp of the putative promoter region upstream of different CYP6ER1 variants. Contig 5 could 
not be assigned to a known CYP6ER1 variant. The position of the sequence breakpoint 
upstream of CYP6ER1vA is illustrated with an arrow. B) Matrix of calculated sequence identity 
of the different promoter variants. 
Name Year collected Country of origin Region/area 
NLS 1984 Japan Unknown 
NLF1 August 2009 Thailand Unknown 
NLF2 
November 2010 Vietnam 
Trà Vinh Province, 
Southern Vietnam 
NLF3 August 2011 Vietnam Hau Giang 
NLF4 
August 2011 Indonesia 
Anjatan District, 
Indramayu 
NLF5 September 2011 India Raipur, Chhattisgarth 
NLF6 
March 2012 India 
Koppal District, 
Karnataka State 
NLF7 
April 2012 India 
East Godavari District, 
Andhra Pradesh 
NLF8 
September 2012 India 
Sidhikerra, Karnataka 
State 
Table S1.  Origin of BPH strains used in this study. Related 
to Figure 1. 
Strain LC50-
value 
[mg/L-1] 
95% limits Slope (+/- SD) RR 
Mortality 
4 mg L-1 
Mortality 
20 mg L-1 
NLS 0.6 0.50-0.70 1.822+/- 0.158 1 - - 
NLF1 111.7 66.05-212 0.891+/- 0.11 186.2 - - 
NLF2 170.2 46.44-5095 0.655+/- 0.221 283.7 - - 
NLF3 >1000 - - 1666 - - 
NLF4 - - - - 16.50 (+/-8.42) 20.20 (+/-4.21) 
NLF5 - - - - 30.14 (+/-8.11) 34.25 (+/-8.14) 
NLF6 - - - - 15.13 (+/-5.67) 58.31 (+/-8.00) 
NLF7 14.49 4.55-30.81 0.653+/- 0.134 24.2 - - 
NLF8 - - - - 15.74 (+/-5.69) 42.42 (+/-8.02) 
Table S2. Sensitivity of susceptible and resistant strains of Nilaparvata lugens to 
imidacloprid topically applied to adult females. Related to Figure 1.  
Data for strain NLS, NLF1, 2, 3, and 7 shows lethal concentrations 50% (LC50 values) determined 
by probit analyses. Data for NL4, 5, 6, and 8 shows percentage mortality (± standard error) at two 
diagnostic doses (LD95 and 5XLD95 of the susceptible strain). 
Oligo Sequence Purpose 
ER1 CDS F1 ATGTGGGAAAACTCGTGGTTGG PCR/sequencing of CYP6ER1 coding sequence 
ER1 CDS F2 GGTTGGCCTAYCTTGTCACAGG PCR/sequencing of CYP6ER1 coding sequence 
ER1 CDS R1 CTAAGTATCTCTCGCTACCAGC PCR/sequencing of CYP6ER1 coding sequence 
ER1 CDS R2 GCTACCAGCTTCAGTGTGAGG PCR/sequencing of CYP6ER1 coding sequence 
CYP6ER1 vL/vF F CATCCATGAGGTCTACGAAG CYP6ER1 variant-specific QPCR 
CYP6ER1 vL/vF R GAGTGCTGAACAGATGGTGT CYP6ER1 variant-specific QPCR 
CYP6ER1 vA F CTTTCTTCACCCCCGCCC CYP6ER1 variant-specific QPCR 
CYP6ER1 vA R CCTGCATGGTCTCGAACATG CYP6ER1 variant-specific QPCR 
CYP6ER1 vB F TCTTGTCACAATCCTGTTGCTG CYP6ER1 variant-specific QPCR 
CYP6ER1 vB R TGGATGCATTTCTTGGACAATACG CYP6ER1 variant-specific QPCR 
CYP6ER1 vC F GAGACTACTTCTGCATCTTTGT CYP6ER1 variant-specific QPCR 
CYP6ER1 vC R GGAAACCATTGGGAAGAATGA CYP6ER1 variant-specific QPCR 
CYP6ER1 vD F AGATCAAATCGGCGGATGGA CYP6ER1 variant-specific QPCR 
CYP6ER1 vD R CGGAATCATCACTTGAGTTCC CYP6ER1 variant-specific QPCR 
CYP6ER1 vE R CCGGAATCATTACTTGAGTTCC CYP6ER1 variant-specific QPCR 
CYP6ER1 vE F GTATGATGAGATCAGATCTGTGA CYP6ER1 variant-specific QPCR 
D099 pUAST F TCACTGGAACTAGGCTAGCA Sequence validation of transgenic flies 
D102 pUAST F GGATCCAAGCTTGCATGCCTG Sequence validation of transgenic flies 
D100 pUAST R AAAGGCATTCCACCACTGCT Sequence validation of transgenic flies 
D101 pUAST R CCACCACTGCTCCCATTCAT Sequence validation of transgenic flies 
ER1 deletion F GCAGAAATGTTGAGGAAATATCCC Sequencing of exon 6 of BPH individuals 
ER1 deletion R1 ACCAAAGGGTATGAAAGAGAAGG Sequencing of exon 6 of BPH individuals 
Ex3 qPCR F2 GAATGTGATTGCCTCCACGG Copy number QPCR of CYP6ER1 
Ex3 qPCR R2 AGCATCAGCAAGTGGGTTCT Copy number QPCR of CYP6ER1 
Ex4 qPCR F2 AACATGAGGTTCACGCCGAA Copy number QPCR of CYP6ER1 
Ex4 qPCR R2 TGCATGAAATCCTTCCTCACCA Copy number QPCR of CYP6ER1 
VGSC qPCR F2 CACCATTGTCACACAGCAGC qPCR of reference gene (VGSC) 
VGSC qPCR R2 CCCTGGAGTAGTGCTTGTCG qPCR of reference gene (VGSC) 
Nl_Actin_F  TAACGAGAGGTTCCGTTGCC  qPCR of reference gene (actin) 
Nl_Actin_R  GACAGGACAGTGTTGGCGTA qPCR of reference gene (actin) 
Nl_α2_tubulin_F  CCACCCTGGAACACTCTGAC  qPCR of reference gene (α2_tubulin) 
Nl_α2_tubulin_R  CGAAGCAGTGATCGAGGACA  qPCR of reference gene (α2_tubulin) 
Table S3. Sequence of oligonucleotide primers used in this study. Related to STAR methods. 
